The observed reduction in perineural thickness, elevation of plasma FGF21 levels, and reduction in gal3 and MDA levels collectively suggest that diosmin and hesperidin could be valuable agents in mitigating the underlying pathophysiology of diabetic neuropathy. This evidence concerns the gene FGF21 and diabetic neuropathy.